Abstract: An imaging method including: a) acquiring N successive positron emission tomography (PET) low resolution images ?i and simultaneously, N successive Ultrafast Ultrasound Imaging (UUI) images Ui of a moving object; b) determining from each UUI image Ui, the motion vector fields Mi that corresponds to the spatio-temporal geometrical transformation of the motion of the object; c) obtaining a final estimated high resolution image H of the object by iterative determination of a high resolution image Hn+1 obtained by applying several correction iterations to a current estimated high resolution image Hn, n being the number of iterations, starting from an initial estimated high resolution image H1 of the object, each correction iteration including at least: i) warping the estimated high resolution image Hn using the motion vector fields Mi to determine a set of low resolution reference images Lni; ii) determining a differential image Di by difference between each PET image ?i and the corresponding low resolution re

Abstract: The invention relates to a method for determining at least one property of an object, the method comprising a step of: a) obtaining first data relative to the object by an ultrasound imaging technique imaging the object at a frame rate superior to 300 Hz, characterized in that the method further comprises a step of: b) obtaining second data relative to the object by imaging the object with at least one of a X-ray and a ?-ray, and c) determining the at least one property of the object based on the first data and the second data.

Abstract: An imaging method including: a) acquiring N successive positron emission tomography (PET) low resolution images ?i and simultaneously, N successive Ultrafast Ultrasound Imaging (UUI) images Ui of a moving object; b) determining from each UUI image Ui, the motion vector fields Mi that corresponds to the spatio-temporal geometrical transformation of the motion of the object; c) obtaining a final estimated high resolution image H of the object by iterative determination of a high resolution image Hn+1 obtained by applying several correction iterations to a current estimated high resolution image Hn, n being the number of iterations, starting from an initial estimated high resolution image H1 of the object, each correction iteration including at least: i) warping the estimated high resolution image Hn using the motion vector fields Mi to determine a set of low resolution reference images Lni; ii) determining a differential image Di by difference between each PET image ?i and the corresponding low resolution re

Abstract: The invention relates to a method for determining at least one property of an object, the method comprising a step of: a) obtaining first data relative to the object by an ultrasound imaging technique imaging the object at a frame rate superior to 300 Hz, characterized in that the method further comprises a step of: b) obtaining second data relative to the object by imaging the object with at least one of a X-ray and a ?-ray, and c) determining the at least one property of the object based on the first data and the second data.

Abstract: The invention relates to polymerized micelles of size inferior to 100 nm for in vivo diagnosis, in particular of cancer. The polymerized micelles of the invention comprise a diagnostic agent and an amphiphilic polymer obtainable by the polymerization of an amphiphilic monomer, said monomer comprising: a lipophilic chain comprising a polymerizable vinylic or diacetylenic group, and a hydrophilic head comprising a polyoxyethylene or polyoxypropylene chain. The invention finds application in the pharmaceutical field, in particular.

Abstract: The present invention relates to a formulation of a therapeutic or diagnostic agent in the form of a nano-emulsion, to its preparation method and to the use of this formulation for treating or diagnosing hormone-dependent cancers or cancers of organs synthesizing steroidal hormones.

Abstract: Use of a radiolabelled form of 7-chloro-?/?,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4/?/?pyridazino[4,5-b]indole-1-acetamide as a biomarker for the detection, in an individual, of PBR levels associated with normal and pathological conditions. Method for the detection of PBR levels associated with normal and pathological conditions. Diagnostic kit.

Abstract: The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (?): —Y—Z—W—R11??(?) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.

Abstract: The present invention relates to a formulation of a therapeutic or diagnostic agent in the form of a nano-emulsion, to its preparation method and to the use of this formulation for treating or diagnosing hormone-dependent cancers or cancers of organs synthesizing steroidal hormones.

Abstract: The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (?): —Y—Z—W—R11??(?) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.

Abstract: A method provides for estimating the concentration of a tracer in a tissue structure assembly including at least one tissue structure, from a measurement image of the tracer concentration in said tissue structure assembly, which is obtained by an imaging apparatus, wherein said image includes at least one space domain inside which the tracer concentration is homogenous and at least one region of interest in which the tracer concentration is measured.

Abstract: The present invention relates to a formulation as a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed phase, and comprising: an amphiphilic lipid, a solubilizing lipid, a hormone, a hormone agonist or antagonist or a mixture thereof, and a co-surfactant comprising at least one chain consisting of alkylene oxide units for its use for hormonal treatment selected from contraception, reproduction assistance, post-menopausal hormonal treatment, treatment of menorrhagias, treatment of acne and treatment of adrenal dysregulations.

Abstract: The invention relates to polymerized micelles of size inferior to 100 nm for in vivo diagnosis, in particular of cancer. The polymerized micelles of the invention comprise a diagnostic agent and an amphiphilic polymer obtainable by the polymerization of an amphiphilic monomer, said monomer comprising: a lipophilic chain comprising a polymerizable vinylic or diacetylenic group, and a hydrophilic head comprising a polyoxyethylene or polyoxypropylene chain. The invention finds application in the pharmaceutical field, in particular.

Abstract: Use of a radiolabelled form of 7-chloro-?/,?/,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4/-/-pyridazino[4,5-b]indole-1-acetamide as a biomarker for the detection, in an individual, of PBR levels associated with normal and pathological conditions. Method for the detection of PBR levels associated with normal and pathological conditions. Diagnostic kit.

Abstract: A method provides for estimating the concentration of a tracer in a tissue structure assembly including at least one tissue structure, from a measurement image of the tracer concentration in said tissue structure assembly, which is obtained by an imaging apparatus, wherein said image includes at least one space domain inside which the tracer concentration is homogenous and at least one region of interest in which the tracer concentration is measured.

Abstract: A compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4) alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6) alkenyl group or a group of formula (y): wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.

Abstract: The present invention relates to a method of segmenting a starting image or sequence of tridimensional images for obtaining a tridimensional segmentation image comprising a partition into regions of interest, said image or sequence of images comprising measurements, for each voxel and in the course of n time intervals (n?1), of the real evolution of a signal representative of at least one variable of said image or sequence, which comprises essentially: a) a modeling (10) of the signal comprising the definition of a parametric model of spatio-temporal evolution of said signal, this model comprising sets of homogeneous parameters respectively specific to structures corresponding to said regions of interest; b) an extraction (30) of samples of voxels respectively included in said structures; then c) a merging (50b) of the samples grouping together those whose evolution model is specific to the same structure, said merging following, preceding or including a classification of all the voxels of said image or se

Abstract: The invention relates to an amplification-free method of screening groups of radioactive molecules, comprising at least the following steps: (1) the group of molecules is administered to at least one animal; (2) at least one of the animals is slaughtered and the tissue distribution of the radioactivity of the molecules administered is analyzed in vivo; (3) sections of tissue or organs in which a radioactivity signal is detected are selected; (4) radioactive fractions from the sections of tissue or organs are isolated using suitable techniques such as chromatography and/or extraction techniques; and (5) the molecule(s) from the radioactive fractions obtained in step 4 are characterized using suitable analysis techniques such as chromatography and/or mass spectrometry.

Abstract: The invention relates to aptamers selected from live tumor cells and to the use thereof for diagnosis and treatment of certain cancers and other pathologies.

Abstract: The luminescence imaging apparatus comprises: a stage receiving a sample (2) emitting luminescence information about the sample; a light source (8) illuminating the stage; and an electronic control unit defining time frames; a combined light signal corresponding to a combination of luminescence information and of the reflection on the sample of the illumination. During each time frame, the detection apparatus (9) acquires both first data relating to the luminescence information, and also second data relating to the second light signal.